FDA Seeks Data On Triclosan, Considers OTC Acne Monograph Inclusion
This article was originally published in The Tan Sheet
Executive Summary
FDA is issuing a call-for-data for information on the safety and effectiveness of triclosan when used as an anti-acne ingredient
You may also be interested in...
Ciba Seeks FDA Clarification On Possible Triclosan “Data Gaps”
Ciba Specialty Chemicals is seeking a meeting with FDA staff to discuss "outstanding issues" relating to triclosan safety, the company says in a recent letter to the agency
Triclosan Antigingivitis/Antiplaque Monograph Status Sought By Ciba
Ciba Specialty Chemicals requests that FDA include triclosan in its upcoming OTC monograph for antigingivitis/antiplaque oral care products in a recently-filed application
Monograph Eligibility To Include U.S. Rx-Only Drugs With Foreign OTC Data
A drug marketed OTC in foreign countries but limited to Rx use in the U.S. could be considered for eligibility in the OTC monograph system under FDA's final rule on "material time, material extent" criteria, published in the Federal Register Jan. 23